Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.49 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18633336 | 0.82 | MAOB (0.54) | MAOBAPPCYP4F2CYP4A11NR4A2 | |
| SCHEMBL30792263 | 0.81 | MAOB (0.53) | MAOBAPPCYP4F2CYP4A11ALKBH1 | |
| SCHEMBL1713718 | 0.81 | P4HTM (0.53) | MAOBALKBH1HDAC6MAOA | |
| SCHEMBL28262789 | 0.79 | MAOB (0.55) | MAOBAPPCYP4F2CYP4A11ALKBH1 | |
| SCHEMBL27550091 | 0.78 | MAOB (0.80) | MAOBAPPNR4A2CA12CA1 | |
| SCHEMBL19604518 | 0.77 | MAOB (0.67) | MAOBAPPNR4A2CA12CA1 | |
| SCHEMBL11959895 | 0.77 | MAOB (0.67) | MAOBAPPNR4A2CA12CA1 | |
| SCHEMBL20804354 | 0.76 | MAOB (0.67) | MAOBAPPNR4A2CA12CA1 | |
| SCHEMBL753107 | 0.75 | GRM2 (0.41) | — | |
| SCHEMBL755812 | 0.75 | MEN1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2266958-B1 | Antiviral agent | SHIONOGI & CO (JP) | 2017-03-15 | — | — | EP | disclosed |
| US-20170066754-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
| US-20170066754-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
| US-20170066754-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
| US-9572813-B2 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2017-02-21 | — | — | US | disclosed |
| US-9572813-B2 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2017-02-21 | — | — | US | disclosed |
| US-9572813-B2 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2017-02-21 | — | — | US | disclosed |
| EP-3042894-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-20150202208-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2015-07-23 | — | — | US | disclosed |
| US-20150202208-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2015-07-23 | — | — | US | disclosed |
| US-20150202208-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2015-07-23 | — | — | US | disclosed |
| EP-1422218-B1 | ANTIVIRAL AGENT | SHIONOGI & CO (JP) | 2012-03-21 | — | — | EP | disclosed |
| EP-1422218-B1 | ANTIVIRAL AGENT | SHIONOGI & CO (JP) | 2012-03-21 | — | — | EP | disclosed |
| EP-2181985-B1 | Antiviral Agent | SHIONOGI & CO (JP) | 2011-10-26 | — | — | EP | disclosed |
| EP-2266958-A1 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2010-12-29 | — | — | EP | disclosed |
| EP-2181985-A1 | Antiviral Agent | SHIONOGI & CO., LTD. (JP) | 2010-05-05 | — | — | EP | disclosed |
| EP-2181985-A1 | Antiviral Agent | SHIONOGI & CO., LTD. (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-20040229909-A1 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
| EP-1422218-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2004-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229909-A1 | Antiviral agent | ZC3HAV1, ZC3HAV1L, DUT | MAOB 709/4885APP 3873/4885CYP4F2 2346/4885 |
| US-20150202208-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | MAOB 900/4885APP 4073/4885CYP4F2 2332/4885 |
| US-20170066754-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | MAOB 900/4885APP 4073/4885CYP4F2 2332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.